Full service firm Skadden is a top tier firm, especially in M&A, debt capital markets, structured finance and securitization, regulatory financial services, restructuring and insolvency and oil and gas projects. It was founded in New York in 1948 and the New York office remains the firm’s headquarters and largest office. It has since, however, expanded to 22 offices across three continents. In the United States, the firm has offices in Boston, Chicago, Houston, Los Angeles, Palo Alto, Washington D.C. and Wilmington.   

Highlights

Across all its practices, Skadden is accustomed innovative transactions. The firm’s M&A department advised Activision Blizzard as the seller in its sizeable all-cash acquisition by Microsoft Corporation. This transaction broke world records in the history of the gaming industry, the technology sector, all-cash transactions and Microsoft Corporation. The firm had similar landmark success in the Japanese pharmaceutical sector, the US utilities sector and the software industry. Furthermore, the firm showed finesse in guiding clients towards authorization from Antitrust authorities and the Food and Drug Administration.

In project finance, the firm led novel transactions in the renewables sector including its representation of the lenders in a first-of-its-kind unguaranteed bridge facility with a unique tax credit sale feature. This is financing a Parliament Solar project. It also represented Pattern Energy Group in the financing of SunZia’s landmark transmission and wind projects. This deal is unprecedented for the US clean energy infrastructure sector.

Key clients 

Key clients for the firm include First BanCorp, Crédit Agricole, Banco Azteca, Centene, Zillow, Bank of America, Scotia Capital, Citigroup, CEMEX, Pfizer, Morgan Stanley, PayPal, Barclays, Eaton Vance, Fair Oaks Capital, AES, BlackRock, Tennenbaum Capital Partners, Caesars Entertainment Corporation, NextEra Energy Partners, Exact Sciences, Array BioPharma, DowDuPont, The Blackstone Group, Aflac, Irish Bank Resolution Corporation, UBS, Synergy Pharmaceuticals and Stearns Holdings.